Organon (OGN) Assets Average (2021 - 2026)
Organon (OGN) posted quarterly Assets Average of $12.9 billion for Q1 2026, down 1.5% year-over-year from $13.1 billion in Q1 2025, and down 2.1% on a QoQ basis from $13.2 billion in Q4 2025.
Organon (OGN) Assets Average (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Assets Average for 6 consecutive years, with $12.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 1.5% year-over-year to $12.9 billion; the TTM figure through Mar 2026 stood at $12.9 billion (down 1.5% YoY), while the FY2025 annual figure was $13.0 billion, up 3.22% from the prior year.
- Assets Average came in at $12.9 billion for Q1 2026 at Organon, down from $13.2 billion in the prior quarter.
- The five-year high for Assets Average was $13.5 billion in Q3 2025, with the low at $10.5 billion in Q3 2022.
- Average Assets Average over 5 years is $11.9 billion, with a median of $12.0 billion recorded in 2024.
- Across the five-year window, Assets Average dropped 5.36% in 2022 and increased 13.26% in 2024, its largest moves.
- Year by year, Assets Average stood at $10.7 billion in 2022, then climbed by 7.84% to $11.5 billion in 2023, then grew by 12.06% to $12.9 billion in 2024, then climbed by 2.19% to $13.2 billion in 2025, then dropped by 2.1% to $12.9 billion in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $12.9 billion, $13.2 billion, and $13.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 12.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.93 Bn |
| Dec 31, 2025 | 13.21 Bn |
| Sep 30, 2025 | 13.53 Bn |
| Jun 30, 2025 | 13.33 Bn |
| Mar 31, 2025 | 13.13 Bn |
| Dec 31, 2024 | 12.93 Bn |
| Sep 30, 2024 | 12.45 Bn |
| Jun 30, 2024 | 12.02 Bn |
| Mar 31, 2024 | 11.97 Bn |
| Dec 31, 2023 | 11.54 Bn |
| Sep 30, 2023 | 11.00 Bn |
| Jun 30, 2023 | 10.87 Bn |
| Mar 31, 2023 | 10.86 Bn |
| Dec 31, 2022 | 10.70 Bn |
| Sep 30, 2022 | 10.53 Bn |
| Jun 30, 2022 | 10.61 Bn |
| Mar 31, 2022 | 10.64 Bn |
| Dec 31, 2021 | 11.01 Bn |
| Sep 30, 2021 | 11.12 Bn |
| Jun 30, 2021 | 10.28 Bn |